First-of-Its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined With Exercise in Older Adults With Hypertension

ChromaDex Corp., the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. This trial will assess the potential of NIAGEN® (NR) to enhance the effects of exercise therapy in older adults with hypertension. ChromaDex’s patent-protected NR is a unique form of vitamin B3 that is proven to safely increase NAD+ levels in the body. NAD+ declines as we age and is a critical coenzyme for cellular energy production and mitochondrial function, both important components of healthy human aging.

“This clinical trial will provide valuable information on the potential of NR supplementation to enhance the benefits of exercise in older populations with hypertension. Published data suggest NR may support cardiovascular health with further study, specifically through improvements in blood pressure (BP) and aortic stiffness. However, older hypertensive adults have yet to be explored in a clinical study,” said primary investigator Robert Mankowski, Ph.D., an assistant professor in the UF Department of Aging and Geriatric Research.

Learn more about First-of-Its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined With Exercise in Older Adults With Hypertension.